Canadian drugmaker Valeant Pharmaceuticals International, Inc. (VRX, VRX.TO) has appointed Ari Kellen to its Executive Management Team and he would assume the role of Executive Vice President/Company Group Chairman, effective January 1, 2014.
Kellen was a senior partner in McKinsey & Company's Mid-Atlantic Office. Since joining McKinsey in March 1991, Ari has led numerous strategy, organization and performance improvement studies for health care companies, including corporate strategies for boards and top management teams, business unit strategies for medical device, pharmaceutical and biotechnology, and health care services clients, and regional and country growth strategies.
Furthermore, Ari has developed business model innovation and turnaround strategies and top level organization structure, governance and decision-making redesigns. Ari directed performance turnarounds addressing revenue, cost, capital and change management.
For comments and feedback: editorial@rttnews.com